Kaiser Permanente GLP-1 Coverage for Weight Loss (2026)

If you have Kaiser Permanente, you probably found conflicting answers about whether it covers GLP-1 medications for weight loss. There is a reason. Kaiser Permanente is an integrated system with regional health plans: its federal employee materials list Northern and Southern California, Colorado, Georgia, Hawaii, Maryland, Virginia and Washington, D.C. (the Mid-Atlantic States), Oregon and Southwest Washington (the Northwest), and Washington.^[1] Each region publishes its own drug formularies and criteria, and inside each region, your plan type and employer can change the answer again.

Here is what Kaiser’s own documents say as of 2026-10-16, and how to get a real answer for your plan.

Transformation Health is an independent guide, not a provider, and is not affiliated with Kaiser Permanente: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.

The short answer

Coverage depends on your Kaiser region and your specific plan. As of 2026-10-16:

• California commercial and Individual and Family plans: GLP-1s prescribed solely for weight loss are not covered under the base plan for members with a BMI under 40, effective with contract renewals on or after January 1, 2025. They stay covered under the base plan at a BMI of 40 or higher, and large employers can buy a weight loss drug rider for broader coverage.^[2][3]
• Northwest region: Wegovy and Zepbound are covered for weight loss only for members whose plan includes coverage for weight loss medications, and only when Kaiser’s criteria are met. Other members pay the cash price.^[4][5]
• Medi-Cal members in California: the state’s Medi-Cal Rx program stopped covering GLP-1s for weight loss only as of January 1, 2026.^[6]
• Federal employees on Kaiser FEHB plans: Kaiser says it offers GLP-1 drugs at 50 percent coinsurance, with prior authorization.^[1]

GLP-1 medications prescribed for type 2 diabetes are a separate coverage category. Kaiser’s California announcement said coverage stays unchanged when these drugs are prescribed as part of a disease management program for conditions such as type 2 diabetes.^[2] This page is about coverage for weight management.

What Kaiser’s regional documents say

Each row comes from a Kaiser Permanente document or, for Medi-Cal, the state’s own notice. Dates are the dates in those documents.

A few cautions about that table. We did not find a current public coverage document for GLP-1s for weight loss from Kaiser’s Colorado, Georgia, or Hawaii regions, or for Mid-Atlantic commercial plans, so those regions are not in the table. That does not mean they cover or exclude these drugs. Kaiser’s California employer page is no longer online; the details above come from an archived copy captured October 18, 2025, and are consistent with Kaiser’s October 2024 member flyer, which is still posted. Employer groups and self-funded plans can also set their own terms.

Northwest criteria for Wegovy and Zepbound

If your Northwest plan includes coverage for weight loss medications, Kaiser’s published criteria for an adult’s first 12-month approval include:^[4][5]

The Northwest criteria also list separate paths for other FDA-approved uses, such as Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea. Kaiser has also posted revised Northwest criteria for both drugs, dated September 10, 2026, with an effective date of November 5, 2026, so ask which version applies when you request coverage.

Kaiser Medicare plans

Kaiser Medicare Advantage plans with drug coverage follow federal Part D rules. The law lets Part D exclude “agents when used for anorexia, weight loss, or weight gain,” so a GLP-1 prescribed for weight loss alone is generally not covered under basic Part D coverage.^[9] Part D plans may cover a GLP-1 for another FDA-approved use, such as type 2 diabetes, and federal rules let plans offering enhanced alternative coverage add supplemental drug benefits.^[10] Separately, CMS is running the Medicare GLP-1 Bridge, a demonstration from July 1, 2026 through December 31, 2027 that gives eligible Part D enrollees access to certain GLP-1 drugs for weight management outside the regular Part D benefit.^[11] Ask Kaiser, and ask CMS or 1-800-MEDICARE whether the Bridge applies to you. Our page on Medicare Part D and GLP-1 coverage covers the details.

How to check your own Kaiser coverage

Most Kaiser members get prescriptions from Kaiser clinicians and fill them at Kaiser pharmacies, so the people who can answer this are inside Kaiser.

Ask your Kaiser care team. Your Kaiser clinician can tell you which criteria apply in your region and whether a GLP-1 is a fit for you clinically. Kaiser’s Northwest criteria also tell members to contact Pharmacy Services in their home region to confirm their benefits for weight loss medications.^[4]

Call member services. Use the number on your Kaiser card and ask three questions. Does my plan cover GLP-1 medications for weight management? If so, which ones, and what criteria apply in my region? Does my plan include a weight loss drug rider? Write down the date and the name of the person you spoke with, because coverage can change at renewal.

Ask your HR benefits team. If you have Kaiser through work, HR can tell you whether your employer bought a weight loss drug rider or otherwise added weight loss medication coverage. In California especially, that choice can be the difference between covered and not covered.

You can also read your Evidence of Coverage or plan summary in your Kaiser member account and search the pharmacy section for weight loss medications. If the benefit exists on your plan, our guide to GLP-1 prior authorization walks through the documentation these requests usually need. If your plan recently dropped coverage, what to do if insurance stopped covering your GLP-1 covers the next steps.

If Kaiser says no

What you do next depends on why the answer was no.

The denial was about criteria or documentation. This is often fixable. A documented BMI, weight-related conditions noted in your chart, and recorded participation in a diet and exercise program address the criteria Kaiser’s published documents use. HealthCare.gov says you generally have 180 days from a denial notice to file an internal appeal, and if that appeal is denied, you can in many cases ask for an independent external review.^[12][13] Medi-Cal members who get a denial notice have the right to a State Hearing, generally within 90 days of the notice.^[6] Start with our guide on what to do when insurance denies your GLP-1.

The medication you want is not on your formulary. Ask Kaiser how to request a formulary exception. Your prescriber’s documentation of why the formulary alternative is not right for you is what carries the request. For individual and small-group plans that must cover essential health benefits, federal rules require an exception process, with a decision due within 72 hours on a standard request and within 24 hours when circumstances are urgent.^[14] Employer plans follow different federal claim rules, and your plan documents state the exact limits that apply to you.

Your plan excludes weight loss medications. An appeal generally cannot override a plan exclusion. You can ask HR whether a weight loss drug rider is under consideration for the next plan year, check whether another plan at open enrollment includes coverage, and ask your prescriber whether any covered use applies to you. Beyond that, the options are outside insurance:

• Manufacturer savings and self-pay options. Novo Nordisk and Eli Lilly each publish savings and self-pay terms, and the terms change. Our page on GLP-1 savings programs compares them.
• Cash-pay telehealth programs. Some prescribe brand-name medications and some prescribe compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.^[15] Our page on compounded GLP-1 without insurance explains how that route works.

Prices vary by program, medication, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. At most telehealth programs, a licensed provider reviews your health history and decides whether a prescription is appropriate. Our page on what insurance covers for weight loss and the full insurance coverage overview can help you weigh the options.

Transformation Health does not accept payment from providers. How we make money.

Citations

[1] Kaiser Permanente. “Weight Management Programs and GLP-1 Requirements for FEHB” (2026 Federal Employees Health Benefits information sheet, all regions). Accessed 2026-10-16. https://choose.kaiserpermanente.org/content/dam/kp/secondsales/microsites/contents/pdf/fehb/2026/All%20Regions_Kaiser%20Permanente%20FEHB%20Weight%20Management%20Programs%20and%20GLP-1%20Requirements.pdf

[2] Kaiser Permanente (California). “Changes for GLP-1 drugs and other Anti-Obesity Medications in 2025” (employer news and announcements, 2024). The live page was unavailable on 2026-10-16; content read from the Internet Archive copy captured October 18, 2025. Accessed 2026-10-16. https://business.kaiserpermanente.org/business/employer/california/news-and-announcements/2024/glp-1-coverage-changes-2025 (archived: https://web.archive.org/web/20251018140953/https://business.kaiserpermanente.org/business/employer/california/news-and-announcements/2024/glp-1-coverage-changes-2025)

[3] Kaiser Permanente. “Your weight loss medication coverage: Changes to 2025 coverage” (member flyer), October 2024. Accessed 2026-10-16. https://business.kaiserpermanente.org/content/dam/kp/bcssp/shared/shared-assets/documents/news-and-announcements/2024/glp1-weight-loss-medication-coverage-flyer.pdf

[4] Kaiser Foundation Health Plan of the Northwest. “Kaiser Permanente Northwest Region Criteria for Coverage: semaglutide (Wegovy).” Revised December 11, 2025; effective February 5, 2026. Accessed 2026-10-16. https://healthy.kaiserpermanente.org/content/dam/kporg/final/documents/formularies/nw/kp-criteria-wegovy-nw-en-commercial.pdf (revised version effective November 5, 2026: https://healthy.kaiserpermanente.org/content/dam/kporg/final/documents/formularies/nw/kp-criteria-wegovy-injection-nw-en-commercial.pdf)

[5] Kaiser Foundation Health Plan of the Northwest. “Kaiser Permanente Northwest Region Criteria for Coverage: tirzepatide (Zepbound).” Revised June 12, 2025; effective August 7, 2025. Accessed 2026-10-16. https://healthy.kaiserpermanente.org/content/dam/kporg/final/documents/formularies/nw/kp-zepbound-nw-en.pdf (revised version effective November 5, 2026: https://healthy.kaiserpermanente.org/content/dam/kporg/final/documents/formularies/nw/kp-criteria-zepbound-nw-en-commercial.pdf)

[6] California Department of Health Care Services, Medi-Cal Rx. “GLP-1 Drugs: Medi-Cal Rx Members’ Frequently Asked Questions (FAQs),” Version 5.0, April 6, 2026. Accessed 2026-10-16. https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/faq/Members_State_Budget_Policy_Updates_FAQ.pdf

[7] Kaiser Foundation Health Plan of Washington. “Provider E-News,” January 2026 (“Wegovy not covered under Kaiser Permanente commercial plans”). Accessed 2026-10-16. https://wa-provider.kaiserpermanente.org/static/pdf/provider/communications/e-news/january-2026.pdf

[8] Kaiser Permanente Health Plan of the Mid-Atlantic States. “Weight Loss Agents Prior Authorization (PA)” form (Virginia Medicaid and FAMIS). Revised March 9, 2026; effective April 7, 2026. Accessed 2026-10-16. https://healthy.kaiserpermanente.org/content/dam/kporg/final/documents/community-providers/mas/ever/virginia-medicaid-famis-prior-authorization-for-weight-loss.pdf

[9] 42 U.S.C. 1395w-102(e)(2)(A) (definition of covered Part D drug; exclusions). Accessed 2026-10-16. https://www.law.cornell.edu/uscode/text/42/1395w-102

[10] 42 CFR 423.104(f)(1) (enhanced alternative coverage; supplemental benefits). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/42/423.104

[11] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge.” Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

[12] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/

[13] HealthCare.gov (Centers for Medicare and Medicaid Services). “External review.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/

[14] 45 CFR 156.122(c) (prescription drug benefits: standard and expedited exception requests). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/45/156.122

[15] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Important disclosures

Coverage information on this page is current as of 2026-10-16, is general and educational, and changes frequently. It does not represent the terms of your specific plan and is not legal advice. Kaiser Permanente sets coverage by region and plan. Confirm current benefits, formulary status, and prior authorization requirements directly with Kaiser Permanente: ask your Kaiser care team, call the member services number on your card, or ask your HR benefits team if you have an employer plan. Medi-Cal members can also call Medi-Cal Rx.